Neurogenic Detrusor Overactivity Is Associated with Decreased Expression and Function of the Large Conductance Voltage- and Ca²⁺-Activated K⁺ Channels

Kiril L. Hristov¹, Serge A. Y. Afeli¹, Shankar P. Parajuli¹, Qiuping Cheng¹, Eric S. Rovner², Georgi V. Petkov¹,²

¹ Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States of America, ² Medical University of South Carolina, Charleston, South Carolina, United States of America

Abstract

Patients suffering from a variety of neurological diseases such as spinal cord injury, Parkinson’s disease, and multiple sclerosis often develop neurogenic detrusor overactivity (NDO), which currently lacks a universally effective therapy. Here, we tested the hypothesis that NDO is associated with changes in detrusor smooth muscle (DSM) large conductance Ca²⁺-activated K⁺ (BK) channel expression and function. DSM tissue samples from 33 patients were obtained during open bladder surgeries. NDO patients were clinically characterized preoperatively with pressure-flow urodynamics demonstrating detrusor overactivity, in the setting of a clinically relevant neurological condition. Control patients did not have overactive bladder and did not have a clinically relevant neurological disease. We conducted quantitative polymerase chain reactions (qPCR), perforated patch-clamp electrophysiology on freshly-isolated DSM cells, and functional studies on DSM contractility. qPCR experiments revealed that DSM samples from NDO patients showed decreased BK channel mRNA expression in comparison to controls. Patch-clamp experiments demonstrated reduced whole cell and transient BK currents (TBKCs) in freshly-isolated DSM cells from NDO patients. Functional studies on DSM contractility showed that spontaneous phasic contractions had a decreased sensitivity to iberiotoxin, a selective BK channel inhibitor, in DSM strips isolated from NDO patients. These results reveal the novel finding that NDO is associated with decreased DSM BK channel expression and function leading to increased DSM excitability and contractility. BK channel openers or BK channel gene transfer could be an alternative strategy to control NDO. Future clinical trials are needed to evaluate the value of BK channel opening drugs or gene therapies for NDO treatment and to identify any possible adverse effects.

Citation: Hristov KL, Afeli SAY, Parajuli SP, Cheng Q, Rovner ES, et al. (2013) Neurogenic Detrusor Overactivity Is Associated with Decreased Expression and Function of the Large Conductance Voltage- and Ca²⁺-Activated K⁺ Channels. PLoS ONE 8(7): e68052. doi:10.1371/journal.pone.0068052

Editor: Steven Barnes, Dalhousie University, Canada

Received January 14, 2013; Accepted May 24, 2013; Published July 5, 2013

Copyright: © 2013 Hristov et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by the National Institutes of Health DK084284 grant to GVP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: petkov@cop.sc.edu

Introduction

Overactive bladder (OAB) is described as urgency, with or without incontinence, usually associated with frequency and nocturia [1]. Patients with various neurological diseases often develop voiding dysfunction which presents clinically as OAB [2]. These OAB symptoms are often caused by dysfunction of the neurological control mechanisms subserving bladder function. When such a condition is the result of uro-dynamically demonstrable involuntary bladder contractions, it is termed neurogenic detrusor overactivity (NDO). The pathology of NDO is often associated with alteration of the electromechanical properties of the detrusor smooth muscle (DSM), including increased DSM excitability [2]. Aside from the clinical symptoms of frequency, urgency and incontinence, high pressure involuntary contractions of DSM in patients with NDO may eventually lead to irreversible changes in DSM. Such changes may result in decreased bladder compliance with associated high intra vesical pressure during the bladder filling phase, and if left untreated may lead to deterioration of the upper urinary tract [3–5].

Currently, there is not an optimal pharmacological agent to treat NDO [6]. Antimuscarinics are used to treat NDO but these agents have limited effectiveness and, due to a lack of specificity for the lower urinary tract, are associated with collateral undesirable adverse effects elsewhere in the body [7–12]. The selective β3-adrenoceptor agonist mirabegron [13,14] has been recently proposed to treat OAB; however its effectiveness in patients with NDO remains uncertain. Newer therapies such as intravesical botulinum toxin [3,15] are not only invasive and expensive but are also associated with safety concerns [3,6,16]. Therefore, novel approaches to treat NDO are urgently needed. A critical step for the development of a new, safe, and more effective therapy for NDO is developing a better understanding of the etiology of NDO and the basic mechanisms that control DSM excitability and contractility in NDO patients.

NDO is characterized by increased spontaneous phasic DSM contractions during the filling phase of urodynamics in an individual with a clinically relevant neurological condition [17,18]. The underlying basis of these spontaneous phasic DSM contractions is the spontaneous action potentials [19]. A number
of different types of K⁺ channels control DSM action potential generation [20]. The large conductance voltage- and Ca²⁺-activated K⁺ (BK) channel is arguably the most important physiologically relevant K⁺ channel involved in the regulation of the DSM action potential, the resting membrane potential, and DSM contractility [20–32]. Iberiotoxin, a selective blocker of the BK channel, inhibits the majority of the whole cell outward K⁺ current, depolarizes the DSM cell resting membrane potential, and increases the contractility of human isolated DSM strips [29]. Because of their prominent physiological role in DSM excitability and contractility, BK channels have been identified as a valid target for the pharmacological or genetic control of OAB [18,21,27,29,31,33–37].

The absence of pore-forming BKα subunits or regulatory BKβ₁ subunits significantly increases DSM contractility and urination frequency in association with detrusor overactivity (DO) [24,26,30,38]. In a rat model of partial urethral obstruction, there was a significant decrease in whole cell BK channel current associated with over a 2-fold reduction in BKα subunit mRNA and protein expression [39]. Recent studies also demonstrated direct involvement of BK channels in the etiology of OAB in patients with benign prostatic hyperplasia (BPH) and DO [33] as well as NDO [18]. These results reinforce the notion of a significant role for the BK channel in DSM function and dysfunction, and suggest that BK channel dysfunction can lead to the OAB phenotype. However, the role of the BK channel in the pathophysiology of NDO has not been investigated.

Here, we used a multidisciplinary experimental approach utilizing qPCR and patch-clamp electrophysiology on freshly-isolated human DSM cells, functional studies on human DSM tissue strip contractility, as well as pharmacological protocols to evaluate if NDO is associated with changes in the DSM BK channel expression and function.

Materials and Methods

Human DSM Tissue Collection

All procedures for human DSM tissue collection were reviewed and approved by the Institutional Review Board of the Medical University of South Carolina (MUSC) under the protocol HR 16918. According to this protocol, human DSM tissues were collected upon written informed consent to participate in this study. Human DSM tissue samples from control and NDO patients were obtained during open bladder surgeries performed for a variety of indications such as bladder cancer, urothelial carcinoma, and ureteral reimplantation for repair of urinary fistula. NDO patients were clinically characterized preoperatively with pressure-flow urodynamics demonstrating DO in the setting of a clinically relevant neurological condition such as spina bifida, cerebral palsy, and spinal cord injury; with or without an American Urological Association (AUA) symptom score >7.

Table 1. qPCR primers for BKα, BKβ₁, BKβ₄ subunits and GAPDH.

|   | Sense | Anti-sense | Product (bp) | Accession Number |
|---|---|---|---|---|
| BKα | TGCCTAAAGCATGATTTG | GCCGACATGCTAAATAATTAG | 400 | NG012270 |
| BKβ₁ | TGCACACCTGATGGACCC | TGCGGAAGACAGTGAAG | 258 | NM004137 |
| BKβ₄ | CATTTGTGGTGAGCTTCT | ACATGTCCGAGGTGG | 168 | NM004137 |
| GAPDH | GGATTTGCTGTATTTGG | GGAAGATGTGATGGGATT | 205 | NM002046 |

bp – base pairs.

doi:10.1371/journal.pone.0068052.t001

Figure 1. Patients with NDO have decreased BKα subunit mRNA expression in DSM. qPCR analyses showing 15.8-fold, 1.1-fold, and 1.6-fold decreases in BKα (A), BKβ₁ (B), and BKβ₄ subunits (C) mRNA expression in NDO DSM tissue (n = 3, N = 3) compared to controls (n = 7, N = 7; **P<0.01). Data are shown as relative mRNA expression normalized to GAPDH.

doi:10.1371/journal.pone.0068052.g001

Control patients did not have OAB (defined as an AUA symptom score <8) and did not have a clinically relevant neurological disease. In this study, 33 patients (19 males and 14 females; 26 Caucasians and 7 African-Americans; 62.4±2.8 years average age) were used. From those 33 patients, 4 were with clinically confirmed NDO (4 females; 2 Caucasians and 2 African-Americans; 46.5±14.8 years average age), and 29 patients (19
males and 10 females; 24 Caucasians and 5 African-Americans; 64.6±2.4 years average age) were without NDO and were used as controls. The DSM specimens were obtained from tumor free regions of the bladder dome, posterior or anterior bladder wall. Two types of DSM samples were collected from each patient. The first sample was stored in ice-cold Ca²⁺-free 1X-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES)-buffered dissection solution ($\textit{Solutions and Drugs}$) and was used to conduct patch-clamp and functional studies on DSM contractility. The second sample was kept in RNAlater solution (QIAGEN GmbH, Hilden, Germany) and was used for qPCR experiments. Both samples were transported under controlled conditions to the laboratory after surgery.

**DSM Cell Isolation for Patch-clamp Experiments**

Human DSM cells for patch-clamp electrophysiological experiments were enzymatically isolated as previously described [21,29,40].

**Quantification of BK Channel Subunits mRNA Message by qPCR**

Total RNA was extracted from both control and NDO DSM tissue using the RNaseasy Mini Kit (QIagen, Hilden, Germany), then reverse-transcribed into cDNA using oligo d(T) primers (Promega, WI, USA), M-MLV Reverse Transcriptase (Promega, WI, USA), dNTP mix (Fermentas Life Sciences, ME, USA) and RNase inhibitor (Applied Biosystems, USA) as previously described [21,29,40]. Specific primers for BKα, BKβ1, BKβ4 subunits, and GAPDH were designed based on the cDNA complete sequences of human genes in Genbank and synthesized by Integrated DNA Technologies (IDT, Coralville, Iowa, USA) (Table 1). qPCR experiments followed a two-step amplification plus melting curve protocol using the IQ™5 Thermo Cycler system (Bio-Rad, California, USA). qPCR experiments were carried out on human DSM tissue cDNA (0.5 μg/μL) using IQ SYBR Green Supermix (Bio-Rad, California, USA). GAPDH was chosen as an internal control gene to analyze BKα, BKβ1, and BKβ4 subunits mRNA relative expression and each sample was run in triplicate. The parameters of the qPCR experiments were as follows: Cycle 1, 95°C for 3 min; cycle 2, 95°C for 10 s, then 61°C for 30 s (repeated 40 times). The melting curve analysis was then run between 61°C and 101°C with 0.5°C increments every 10 s. qPCR products were purified using the GenElute™ PCR Clean-Up Kit (Sigma-Aldrich Co., St. Louis, MO, USA) and sequenced at the University of South Carolina Environmental Genomics Core Facility to confirm their identity.

**Electrophysiological (Patch-clamp) Recordings**

The amphotericin-B perforated whole cell configuration of the patch-clamp technique was used [41,42]. This approach allows the preservation of the native physiological environment of human DSM cells. Whole cell currents were recorded using an Axopatch 200B amplifier, Digitida 1440A, and pCLAMP version 10.2 software (Molecular Devices, Union City, CA). The signals were filtered by an eight-pole Bessel filter 900CT/9L8L (Frequency Devices). The patch-clamp pipettes were made from borosilicate glass (Sutter Instruments, Novato, CA), coated with dental wax to reduce capacitance, and polished with a Micro Forge MF-830 fire polisher (Narishige Group, Tokyo, Japan) to give a final tip resistance of 4–6 MΩ. All electrophysiological experiments were conducted at room temperature (22–23°C).

**Solutions and Drugs**

The Ca²⁺-free dissection solution had the following composition (in mM): 80 monosodium glutamate, 55 NaCl, 6 KCl, 10 glucose, 10 HEPES, 2 MgCl₂, and pH 7.3 adjusted with NaOH. The Ca²⁺-containing PSS used in DSM tension recording experiments was prepared daily and contained (in mM): 119 NaCl, 4.7 KCl, 24 NaHCO₃, 1.2 KH₂PO₄, 2.5 CaCl₂, 1.2 MgSO₄ and 11 glucose, and aerated with 95% O₂/5% CO₂ to obtain pH 7.4. The extracellular (bath) solution used in the patch-clamp experiments had the following composition (in mM): 134 NaCl, 6 KCl, 1 MgCl₂, 2 CaCl₂, 10 glucose, and 10 HEPES, pH adjusted to 7.4 with NaOH. The pipette solution used in the patch-clamp experiments contained (in mM): 110 potassium aspartate, 30 KCl, 10 NaCl, 1 MgCl₂, 10 HEPES, and 0.05 EGTA, pH adjusted to 7.2 with NaOH and supplemented with freshly dissolved (every 1–2 h) 200 μg/ml amphotericin-B. Iberiotoxin and tetrodotoxin (TTX) were purchased from Sigma-Aldrich Co.

**Data Analysis and Statistics**

mRNA relative expression was analyzed using the comparative threshold (Ct) method (ΔΔCt, delta-delta Ct) [43] after determining the Ct values for reference (GAPDH) and target genes (BKα, BKβ1, and BKβ4 subunits) for each sample. Fold-changes in target mRNA expression level were calculated after normalization to GAPDH. MiniAnalysis (Synaptosoft, Inc., Decatur, GA) software version 6.0.7 was used to analyze data and GraphPad Prism 4.03 software (GraphPad Software Inc., San Diego, CA) was used for further statistical analysis. To compare the phasic contraction parameters, data were normalized to the control spontaneous contractions (100%) prior to addition of iberiotoxin and expressed as percentages. Clampfit 10.2 software (Molecular Devices, Inc.) was used for the data analysis of the patch-clamp experiments. The data and original recordings were illustrated using GraphPad Prism and CorelDraw Graphic Suite X3 (Corel Co., Ottawa, Canada) software. Results are summarized as mean±SE where N represents the number of patients, n represents the number of human DSM isolated strips, PCR samples, or human DSM cells. Data were compared using twotailed paired or unpaired Student’s t-test. A P-value <0.05 was considered statistically significant.

**Results**

The Relative Expression Levels of BKα Subunit mRNA is Significantly Decreased in NDO DSM

Recently, we established that human DSM cells express BKα, BKβ1, and BKβ4 subunits at both mRNA and protein levels [29]. Here, we revealed that in patients with NDO, the BKα, BKβ1, and BKβ4 subunit mRNA expression was lower compared to control patients (Fig. 1). There was a 15.8-fold decrease in BKα.
Figure 2. Iberiotoxin-sensitive steady-state BK current is significantly reduced in human NDO DSM cells compared to controls.

Original recordings illustrating the effect of 200 nM iberiotoxin on the voltage-dependent steady-state whole cell current in a control DSM cell (A) and in an NDO DSM cell (B). Current-voltage relationships illustrating the differences in whole cell current density in the absence or presence of 200 nM iberiotoxin in control DSM cells (n = 9, N = 9; *P < 0.05) (C) and NDO DSM cells (n = 8, N = 4; P > 0.05) (D).

doi:10.1371/journal.pone.0068052.g002

subunit mRNA relative expression in NDO DSM (n = 3, N = 3) compared to controls (n = 7, N = 7; P < 0.01; Fig. 1). The changes in BKβ1 and BKβ4 subunits in NDO DSM compared to controls were not statistically significant and were evaluated at 1.1-fold and 1.6-fold decrease, respectively (P > 0.05; Fig. 1). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal
control and did not vary significantly between DSM samples from control and NDO patients. These data suggest that in patients suffering from NDO, there is a statistically significant decrease in BKα subunit expression but not in BKβ1 and BKβ4 subunit expression.

Iberiotoxin-sensitive Whole Cell BK Current is Decreased in NDO DSM Cells

We recently showed that the BK channel is the major regulator of human DSM excitability [21,29]. Here, we examined whether DSM BK channel activity changes during NDO. The average human DSM cell capacitance was 24.4±2.7 pF in NDO DSM cells (n = 16, N = 4), and 20.6±2.2 pF in control DSM cells (n = 20, N = 13; P > 0.05). Human DSM cells were held at −70 mV and then stepped from 0 mV to +80 mV in 20 mV increments with 200 ms duration. The cells responded with a gradual increase of the whole cell current with each depolarization step (Fig. 2). Application of the selective BK channel inhibitor, iberiotoxin (200 nM), significantly decreased the whole cell current in DSM cells from control patients (n = 9, N = 4; P < 0.05; Fig. 2A). Figure 2 illustrates that the iberiotoxin-sensitive BK current represented more than 50% of the total outward current in DSM cells from control patients. However, iberiotoxin (200 nM) did not significantly affect the amplitude of the whole cell outward current in DSM cells from NDO patients (Fig. 2B). Figure 2 also illustrates that the iberiotoxin-sensitive BK current represented a very small portion of the total cell current in NDO DSM cells, whereas iberiotoxin (200 nM) significantly reduced the whole cell outward current in DSM cells from control patients (Fig. 2C). There was no significant difference in the current density before and after application of 200 nM iberiotoxin in NDO DSM cells (n = 8, N = 4; P > 0.05; Fig. 2D). These data showed that the iberiotoxin-sensitive BK current was significantly reduced in NDO DSM cells.

Transient BK Currents (TBKCs) Amplitude and Frequency are Decreased in NDO DSM Cells

Recently, we provided the first electrophysiological evidence for the presence of TBKCs in human DSM cells [29]. Here, we examined if the activity of TBKCs in DSM cells changes under pathological conditions of NDO. TBKCs’ amplitude and frequency were significantly reduced in DSM cells in patients with NDO (n = 9, N = 3) compared to the control group (n = 12, N = 10; P < 0.05; Fig. 3). The results indicate that TBKC activity was significantly reduced in NDO DSM cells.
Pharmacological Inhibition of the BK Channels with Iberiotoxin has a Reduced Effect on the Contractility of DSM Strips Isolated from Patients with NDO

To restrain neuronal activity, TTX (1 μM), a selective voltage-gated Na⁺ channel blocker, was added to the bath in the beginning of all experiments. In DSM strips isolated from control patients, iberiotoxin (200 nM) considerably increased the phasic contraction amplitude, muscle force integral, and muscle tone by 81.9±38.7%, 96.9±37.7%, and 14.4±8.3%, respectively (n=12, N=7; P<0.05; Fig. 4A, C). However, in DSM strips isolated from patients with NDO, iberiotoxin (200 nM) had no significant effects on any of the parameters of DSM contractility, including phasic contraction amplitude, muscle force integral, and muscle tone (n=13, N=3; P>0.05; Fig. 4B, C). Collectively, these results suggest a decrease in BK channel activity in DSM from patients with NDO, which contributes to the increase in the spontaneous phasic contractions.

Discussion

In the present study, we found significant physiological differences between control and NDO human tissues and cells that reveal important insights into the etiology of NDO. Using a combined multidisciplinary approach, we provide evidence for a critical role of the BK channel in the pathophysiology of NDO and demonstrate a significant decrease in the function of the BK channels in the DSM of such patients. Based on our experimental data, we have noted three important key results. First, mRNA expression of the pore-forming BKα subunit was significantly decreased in NDO DSM compared to controls. Secondly, whole cell BK current and TBKCs were both significantly decreased in NDO DSM cells compared to controls. Thirdly, inhibition of the BK channels with iberiotoxin did not significantly affect the spontaneous NDO DSM contractions, but did so in control DSM tissues, supporting the concept that NDO tissue is fundamentally biologically altered.

Recently, we provided molecular evidence for the expression of the BKα, BKβ1, and BKβ4 subunits in human DSM cells at both the mRNA and protein levels [29]. Here, we investigated whether the expression of BK channel subunits was altered in DSM from NDO patients. The results showed a 15.8-fold decrease of mRNA expression of the pore-forming BKα subunit but no statistical changes in BKβ1 and BKβ4 subunit mRNA expression in NDO DSM as compared to control DSM (Fig. 1). This is the first molecular evidence for decreased BK channel expression in DSM from NDO patients. The BKα subunit plays a critical role in DSM function, since it forms the functional pore of the BK channel [24,28,30], whereas the DSM BKβ1 subunits have a regulatory role by increasing BK channel Ca²⁺ sensitivity and modifying BK current activity [20,26]. The functional role of BKβ4 subunit in DSM is still unclear [29]. Therefore, any changes in the BKα or BKβ1 subunits’ molecular expression could significantly impact DSM excitability and contractility. This has been well demonstrated in studies with genetically modified mice [24,26,28,30,38]. Deletion of the BKα subunit depolarizes DSM cell membrane potential [24,28], increases DSM contractility [24,30], and results in a phenotype consistent with DO [24,30,38]. The absence of the smooth muscle specific BKβ1 subunit causes an increase in DSM contractility in mice, which suggests that BKβ1 subunit is also an important regulator of DSM function [26]. Decreased mRNA expression of BKα and BKβ1 subunits was observed in animal models of partial urethral outlet obstruction [33,39,44]. Furthermore, patients with BPH and associated DO had a significantly reduced mRNA and protein expression of BKα and BKβ subunits [33]. Our results are consistent with the above study, as we demonstrated that in NDO patients, the mRNA expression of BKα subunit is significantly decreased. These studies support the concept that the NDO phenotype is associated with decreased BK channel expression in DSM.
The patch-clamp results are consistent with our qPCR data, and illustrate that BK channel function is significantly reduced in NDO DSM compared to control DSM.

In patients without symptoms of OAB, the BK channel is also a major regulator of DSM contractility [29]. In the present study, we investigated how the decreased activity of the BK channel affects DSM phasic contractions in NDO patients. Unlike control DSM, inhibition of the BK channel with iberiotoxin did not significantly affect any of the parameters of spontaneous DSM contractility in NDO DSM isolated strips (Fig. 4). These results are supported by a recent study reporting no effect of iberiotoxin or NS1619, a BK channel opener on DSM phasic contractions in patients with NDO [18]. The results from our functional studies support the concept that BK channel activity is decreased in NDO DSM.

The complex etiology of NDO is not completely understood. Our results provide strong evidence that decreased BK channel activity is associated with NDO. Telegologically, this may be a consequence of a compensatory or adaptive mechanism in neurologically affected individuals that leads to increased DSM contractility allowing optimization of bladder emptying in the absence of normal innervation. Similar decreases in BK channel expression and activity have been reported in DSM from patients with BPH and DO, which is a condition with a different etiology than NDO [33]. One of the possible explanations for these similarities is that both conditions, regardless of their etiology, utilize similar compensatory mechanisms to decrease the expression of BK channels in DSM, and thus to alter DSM contractility.

Recently, we found that the selective BK channel opener NS1619 significantly decreased human DSM excitability and contractility [21]. We expect that a selective BK channel opener would be a highly effective treatment for NDO. However, currently available agents are not selective for DSM tissue resulting in collateral effects elsewhere in the body. Nevertheless, there is an ongoing effort to develop a new class of more potent and selective BK channel openers [45]. A genetic approach to enhance BK channel expression could also be a successful therapeutic strategy. Injection of BK channel naked DNA has been shown to eliminate bladder overactivity caused by partial urethral outlet obstruction in rats [35]. A clinical Phase I safety trial of plasmid based gene therapy using BK channel hSlo cDNA has been completed for erectile dysfunction and a future clinical trial is planned for the treatment of patients with OAB [36,37].

In conclusion, this study provides a significant contribution to our basic understanding of the key functional role of the BK channels in NDO. We demonstrated a decrease in the mRNA expression level of the pore-forming BKβ2 subunit in DSM from NDO patients. Furthermore, we provided evidence for BK channel activity in NDO DSM by using the perforated patch-clamp approach, and revealed decreased whole cell BK currents and TBKCs in the DSM cells from NDO patients. These results are consistent with our functional studies showing a lack of an effect of iberiotoxin on spontaneous contractility in NDO DSM isolated strips. These findings support the pursuit and investigation of novel treatments for NDO which target the BK channel. Our results support the concept that BK channel openers and BK channel gene transfer could be an alternative strategy to control NDO as compared to currently prescribed antimuscarinics.

Acknowledgments

We would like to thank MUSC Urology staff surgeons: Drs. Thomas Keane, Harry Clarke, Stephen Savage, Ross Rames and Jonathan Picard, and Ahmed M. El-Zawahry, as well as the MUSC Urology Residents: Avi C. Weiss, Gary W. Bong, Kelly Doyle, Matthew McIntyre, Matt Esbridge, Jonathan N. Hamilton, Robin Blavac, Timothy R. Yoost, Vinh Q. Trang, Lydia Labocetta, Elizabeth Peacock, Matthew Young, Erin Burns, Vaughan Taylor, and Samuel Walker Nickles for their help with human tissue collection; Ms. Whitney F. Kellett for her help with some of the experiments; and Drs. John Malyesz, Wenkun Xia, Rupal Soder, and Ms. Amy Smith for the critical evaluation of the manuscript.

Author Contributions

Conceived and designed the experiments: GVP. Performed the experiments: KLH SAYA ESR GVP. Analyzed the data: KLH SAYA QCP GVP. Wrote the paper: KLH SAYA ESR GVP.

References

1. Abrams P, Cardozo L, Fall M, Grifftus D, Rosier P, et al. (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61: 3–9.
2. Anderson KE, Wein AJ (2004) Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 56: 501–631.
3. Kuo YC, Kuo HC (2013) Botulinum toxin injection for lower urinary tract dysfunction. Int J Urol 20: 40–55.
4. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, et al. (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20: 327–336.
5. Cardenas DD, Mayo ME, Turner LR (1995) Lower urinary changes over time in suprasacral spinal cord injury. Paraplegia 33: 326–329.
6. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, et al. (2008) Refractory idiopathic overactive bladder and botulinum A injection. J Urol 180: 217–222.
7. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, et al. (2008) Refractory idiopathic overactive bladder and botulinum A injection. J Urol 180: 217–222.
8. Wag A, Wyndaele JJ, Sieber P (2006) Efficacy and tolerability of solifenacin in elderly patients with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 4: 14–24.
9. Zinner N, Susset J, Gittelman M, Arguinzoni M, Rekeda L, et al. (2006) Efficacy, tolerability and safety of darifenacin, an M3-selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract 60: 118–126.
10. Stasinakis DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, et al. (2009) Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 181: 1764–1772.
11. Armstrong RB, Dmochowski RR, Sand PK, Macdiarmid S (2007) Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol 39: 1009–1017.
12. Oefelein MG (2011) Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 34: 735–754.
13. Gras J (2012) Mirabegron for the treatment of overactive bladder. Drugs Today (Barc) 48: 25–32.
14. Tsog P, Tsay V (2010) Mirabegron, a beta(3)-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. Drugs 73: 171–722.
15. Conte A, Giannantoni A, Proietti S, Giovanniozzi S, Fabbrini G, et al. (2012) Botulinum toxin A modulatesafferent fibers in neurogenic detrusor overactivity. Eur J Neurol 19: 725–732.
16. Kuo HC, Liao CH, Chung SD (2010) Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 58: 919–926.
17. Branding AF (1997) A myogenic basis for the overactive bladder. Urology 50: 57–67; discussion 68–73.
18. Oger S, Behr-Roussel D, Gorny D, Bernache J, Comperat E, et al. (2011) Effects of potassium channel modulators on myogenic spontaneous phasic contractile activity in human detrusor from neurogenic patients. BJU Int 108: 604–611.
19. Hashinshi H, Brading AF, Suzuki H (2004) Correlation between spontaneous electrical, calcium and mechanical activity in detrusor smooth muscle of the guinea-pig bladder. Br J Pharmacol 141: 183–193.
20. Petkov GV (2012) Role of potassium ion channels in detrusor smooth muscle function and dysfunction. Nat Rev Urol 9: 30–40.
21. Hristov KL, Paqariqi SP, Soder RP, Chung Q, Roovers EJ, et al. (2012) Suppression of human detrusor smooth muscle excitability and contractility via pharmacological activation of large conductance Ca(2+)/activated K+ channels. Am J Physiol Cell Physiol: C163–1641.
22. Hayase M, Hashitani H, Kohri K, Suzuki H (2009) Role of K+ channels in regulating spontaneous activity in detrusor smooth muscle in situ in the mouse bladder. J Urol 181: 2353–2360.
23. Heppner TJ, Bonev AD, Nelson MT (1997) Ca2+-activated K+ channels regulate action potential repolarization in urinary bladder smooth muscle. Am J Physiol 273: C110–117.
24. Brown SM, Bentscheva-Petkova LM, Liu L, Hristov KL, Chen M, et al. (2000) Beta-adrenergic relaxation of mouse urinary bladder smooth muscle in the absence of large-conductance Ca2+-activated K+ channel. Am J Physiol Renal Physiol 285: F1149–1157.
25. Herrera GM, Nelson MT (2002) Differential regulation of SK and BK channels by Ca2+ signals from Ca2+ channels and ryanodine receptors in guinea-pig urinary bladder myocytes. J Physiol 541: 403–407.
26. Petkov GV, Bonev AD, Heppner TJ, Brenner R, Aldrich RW, et al. (2001) Beta1-subunit of the Ca2+-activated K+ channel regulates contractile activity of mouse urinary bladder smooth muscle. J Physiol 557: 443–452.
27. Petkov GV, Nelson MT (2003) Differential regulation of Ca2+-activated K+ channels by beta-adrenoceptors in guinea pig urinary bladder smooth muscle. Am J Physiol Cell Physiol 288: C1255–1263.
28. Sproussmann F, Pankert P, Saubier U, Wirth A, Zhou XB, et al. (2009) Inducible knockout mice: evidence for compensatory mechanisms elicited by constitutive BK channel deficiency in overactive murine bladder. FEBS J 276: 1680–1690.
29. Hristov KL, Chen M, Kellett WF, Rovner ES, Petkov GV (2011) Large-conductance voltage- and Ca2+-activated K+ channels regulate human detrusor smooth muscle function. Am J Physiol Cell Physiol 301: C903–912.
30. Meredith AL, Thorneloe KS, Werner ME, Nelson MT, Aldrich RW (2004) Overactive bladder and incontinence in the absence of the BK large-conductance calcium-activated potassium channel. J Biol Chem 279: 36746–36752.
31. Soder RP, Petkov GV (2011) Large-conductance Ca2+-activated K+ channel activation with NS1619 decreases myogenic and neurogenic contractions of rat detrusor smooth muscle. Eur J Pharmacol 670: 252–259.
32. Xin W, Cheng Q, Soder RP, Petkov GV (2012) Inhibition of phosphodiesterases relaxes detrusor smooth muscle via activation of the large-conductance voltage- and Ca2+-activated K+ channel. Am J Physiol Cell Physiol 302: C1361–1370.
33. Chang S, Gomes CM, Hypolite JA, Marx J, Alanzi J, et al. (2010) Detrusor overactivity is associated with desregulation of large-conductance calcium- and voltage-activated potassium channel protein. Am J Physiol Renal Physiol 298: F1416–1423.
34. Nardi A, Olesen SP (2008) BK channel modulators: a comprehensive overview. Curr Med Chem 15: 1126–1146.
35. Layne JJ, Nausch B, Olesen SP, Nelson MT (2010) BK channel activation by NS11021 decreases excitability and contractility of urinary bladder smooth muscle. Am J Physiol Regul Integr Comp Physiol 298: R378–384.
36. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G (2007) Plasmid-based gene transfer for treatment of erectile dysfunction and overactive bladder: results of a phase I trial. Isr Med Assoc J 9: 143–146.
37. Melman A, Nardelli S, Davies K, Zhao W, Tar MT, et al. (2008) Gene transfer with a vector expressing Maxi-K from a smooth muscle-specific promoter restores erectile function in the aging rat. Gene Ther 15: 364–370.
38. Horn R, Marty A (1988) Muscarinic activation of ionic currents measured by a new whole-cell recording method. J Gen Physiol 92: 145–159.
39. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981) Improved patchclamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391: 85–100.
40. Horn R, Marty A, Neher E, Sakmann B, Sigworth FJ (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391: 85–100.
41. Layne JJ, Nausch B, Olesen SP, Nelson MT (2010) BK channel activation by NS11021 decreases excitability and contractility of urinary bladder smooth muscle. Am J Physiol Regul Integr Comp Physiol 298: R378–384.
42. Horn R, Marty A (1988) Muscarinic activation of ionic currents measured by a new whole-cell recording method. J Gen Physiol 92: 145–159.
43. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.
44. Li L, Jiang C, Song B, Yan J, Pan J (2008) Altered expression of calciumactivated K+ channels in detrusor overactivity of rats with partial bladder outlet obstruction. BJU Int 101: 1588–1594.
45. Nardi A, Olesen SP (2008) BK channel modulators: a comprehensive overview. Curr Med Chem 15: 1126–1146.